Bloomberg Businessweek Investing in Life Sciences
May 11, 2026
Jenny Rook, founder and managing director of Genoa Ventures, invests at the intersection of tech and healthcare. She discusses why oncology remains a central focus. She highlights advances in proteomics and the need for protein-level data. She explains how AI in diagnostics depends on better biomedical datasets and how data, analysis, and workflow integration create clinical value.
AI Snips
Chapters
Transcript
Episode notes
Public Markets Drive AI And Biotech Investment
- Public market interest in biotech fuels demand for AI tools and later-stage capital that accelerate drug development.
- Jenny Rook links IPO activity and big funds to increased investment in AI-driven discovery and clinical advancement.
Cancer Investment Persists Because The Disease Is Complex
- Oncology remains the top area for therapeutic investment because it's prevalent and complex, not a single disease.
- Rook emphasizes cancer's heterogeneity and that it’s increasingly a disease of aging as people live longer.
Proteomics Is The Next Data Frontier
- Proteomics is crucial because proteins are the 'business end' of biology and reveal disease mechanisms more directly than DNA alone.
- Rook highlights Alomar Bio's NASDAQ IPO as evidence of demand for higher-precision protein measurement.